Effects of a 1-year supplementation with cholecalciferol on interleukin-6, tumor necrosis factor-alpha and insulin resistance in overweight and obese subjects

Cytokine

Volumn 60, Issue 3, 2012, Pages 870-874

  Beilfuss, Julia ^a,b   Berg, Vivian ^a   Sneve, Monica ^c   Jorde, Rolf ^b   Kamycheva, Elena ^a,b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Insulin resistance; Interleukin 6; Obesity; TNF ; Vitamin D

Indexed keywords

C REACTIVE PROTEIN; COLECALCIFEROL; INSULIN; INTERLEUKIN 6; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLECALCIFEROL; DIETARY SUPPLEMENTS; FEMALE; HUMANS; INSULIN RESISTANCE; INTERLEUKIN-6; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

ANIMALIA;

EID: 84867987339     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.07.032     Document Type: Article

References (47)

1. Holick M.F., Chen T.C., Lu Z., Sauter E. Vitamin D and skin physiology: a D-lightful story. J Bone Miner Res 2007, 22:28-33.
2. Lagunova Z., Porojnuci A.C., Grant W.B., Bruland Ø., Moan J. Obesity and increased risk of cancer: does decrease of serum 25-dihydroxyvitamin D level with increasing body mass index explain some of the association?. Mol Nutr Food Res 2010, 54:1127-1133.
3. Zitterman A., Vitamin D. In preventive medicine: are we ignoring the evidence?. Br J Nutr 2003, 89:552-572.
4. Holick M.F. The vitamin D epidemic and its health consequences. J Nutr 2005, 92:2739-2748.
5. Bikle D. Nonclassic actions of vitamin D. J Clin Endocrinol Metab 2009, 94:26-34.
6. Zitterman A., Guitierrez O.M. Nonclassical vitamin D actions. Nutrients 2010, 2:408-425.
7. Kamen D.L., Cooper G.S., Bouali H., Shaftman S.R., Hollis B.W., Gilkeson G.S. Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev 2006, 5:114-117.
8. Lips P. Vitamin D physiology. Prog Biophys Mol Biol 2006, 92:4-8.
9. Prosnitz AR, Leonard MB, Shults J, Zemel BS, Hollis BW, Denson LA, Baldassano RN, Cohen AB, Thayu M. Changes in vitamin D and parathyroid hormone metabolism in incident pediatric Crohn's disease. Inflamm Bowel Dis 2012;10 [Epub ahead of print].
10. Jahnsen J., Falch J.A., Mowinckel P., Aadland E. Vitamin D status, parathyroid hormone and bone mineral density in patient with inflammatory bowel disease. Scand J Gastroenterol 2002, 37:192-199.
11. Munger K.L., Levin L.B., Hollis W., Howard N.S., Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296:2832-2838.
12. Grant W.B. Ecological studies of the UVB-vitamin D - cancer hypothesis. Anticancer Res 2012, 32:223-236.
13. Povvedini D.M., Tsoukas C.D., Deftos L.J., Manolagas S.C. 1,25 Dihydroxyvitamin D3 receptors in human leucocytes. Science 1983, 221:1181-1183.
14. Veldman C.M., Cantorna M.T., DeLuca H.F. Expression of 1,25 dihydroxyvitamin D(3)receptor in the immune system. Arch Biochem Biophys 2000, 374:334-338.
15. Hardy J., Singleton A. Genomewide association studies and human disease. N Engl J Med 2009, 23:1759-1768.
16. Penna G., Adorini L. 1 Alpha, 25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000, 164:2405-2411.
17. Daniel C., Sartory N.A., Zahn N., Radeke H.H., Stein J.M. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th)1/Th17 to a Th2 and regulatory T cell profile. J Pharmcol Exp Ther 2008, 324:23-33.
18. Carswell E.A., Old L.J., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975, 72:3666-3670.
19. Strieter R.M., Kunkel S.M., Bone R.C. Role of tumor necrosis factor-alpha in disease states and inflammation. Crit Care Med 1993, 21:S447-S463.
20. Rink L., Kirchner H. Recent progress in the tumor necrosis factor-alpha field. Int Arch Allergy Immunol 1996, 111:199-209.
21. Angus T., Geiger T., Hirano T., Kishimoto T., Heinrich P.C. Action of recombinant human interleukin 6, interleukin 1 beta and tumor necrosis factor alpha on the mRNA induction of acute-phase proteins. Eur J Immunol 1988, 18:736-746.
22. Tilg H., Trehu E., Atkins M.B., Dinarello C.A., Mier G.W. Interleukin 6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994, 83:113-118.
23. Illán-Gómez F, González-Ortega M, Orea-Soler I, Alcaraz-Tafalla MS, Aragón-Alonso A, Pascual-Diaz M, Pérez-Paredes M, Lozano-Almela ML. Obesity and inflammation: change in adiponectin, C reactive protein, tumor necrosis factor-alpha and interleukin-6 after bariatric surgery. Obes Surg 2012;13 [Epub ahead of print].
24. Kamycheva E., Jorde R., Figenschau Y., Haug E. Insulin sensitivity in subjects with secondary hyperparathyroidism and the effect of a low serum 25-hydroxyvitamin D level on insulin sensitivity. J Endocrinol Invest 2007, 30:126-132.
25. Stojanovic O.L., Lazovic M., Vuceljic M. Association between atherosclerosis and osteoporosis, the role of vitamin D. Arch Med Sci 2011, 7:178-188.
26. von Hurst P.R., Stonehouse W., Coad J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient - a randomised, placebo-controlled trial. Br J Nutr 2010, 103:549-555.
27. Rock CL, Emond JA, Flatt SW, Heath DD, Karanja N, Pakiz B, Sherwood NE, Thomson CA. Weight loss is associated with increased serum 25-hydroxyvitamin D in overweight or obese women. Obesity 2012;10 [Epub ahead of print].
28. Jorde R., Sneve M., Torjesen P.A., Figenschau Y., Gøransson L.G., Omdal R. No effect of supplementation with cholecalciferol on cytokines and markers of inflammation in overweight and obese subjects. Cytokine 2010, 50:175-180.
29. Coppack S.W. Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 2001, 60:349-356.
30. Chudek J., Wiecek A. Adipose tissue, inflammation and endothelial dysfunction. Pharmacol Rep 2006, 58:S81-S88.
31. Wolfson N, Gavish D, Matas Z, Boaz M, Shargorodsky M. Relation of adiponectin to glucose tolerance status, adiposity, and cardiovascular risk factor load. Exp Diabetes Res 2012 [Epub ahead of print].
32. Hu F.B., Meigs J.B., Li T.Y., Rifai N., Manson J.E. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004, 53:693-700.
33. Ridker P.M., Rifai N., Stampfer M.J., Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101:1767-1772.
34. Langenberg C., Bergstrom J., Scheidt-Nave C., Pfleischifter J., Barret-Connor E. Cardiovascular death and the metabolic syndrome-role of adiposity-signaling hormones and inflammatory markers. Diabetes Care 2006, 29:1363-1369.
35. Boydens C, Maenhaut N, Pauwels B, Decaluwe K, van der Voorde J. Adipose tissue as a regulator of vascular tone. Curr Hypertens Rep 2012;14 [Epub ahead of print].
36. Clement K., Viguerie N., Poitou C., Carette C., Pelloux V., Curat C.A., et al. Weight loss regulates inflammation-regulated genes in white adipose tissue of obese subjects. FASEB J 2004, 18:1657-1659.
37. Abbatecola A.M., Ferrucci L., Grella R., Bandellini S., Bonafè M., Barbieri M., et al. Diverse effect of inflammatory markers on insulin resistance and insulin-resistance syndrome in the elderly. J Am Geriatr Soc 2004, 52:399-404.
38. Bruun J.M., Verdich C., Toubro S., Astrup A., Richelsen B. Association between measures of insulin sensitivity and circulating levels of interleukin-8, interleukin-6 and tumor necrosis factor-alpha. Effect of weight loss in obese men. Eur J Endocrinol 2003, 148:535-542.
39. Marques-Vidal P, Bastardot F, von Känel R, Paccaud F, Preisig M, Waeber G, Vollenweider P. Association between circulating cytokine levels, diabetes and insulin resistance in a population-based sample (CoLaus study). Clin Endocrinol 2012;12 [Epub ahead of print].
40. Shab-Bidar S, Neyestani TR, Djazayery A, Eshraghian MR, Houshiarrad A, Kalayi A, Shariatzadeh N, Khalaji N, Gharavi A. Improvement of vitamin D status resulted in amelioration of biomarkers of systemic inflammation in the subjects with type 2 diabetes. Diabetes Metab Res Rev 2012;17 [Epub ahead of print].
41. Peterson C.A., Heffernan M.E. Serum tumor necrosis factor-alpha concentrations are negatively correlated with serum 25(OH)D concentrations in healthy women. J Inflamm 2008, 24:5-10.
42. Shedeed SA. Vitamin D supplementation in infants with chronic congestive heart failure. Pediatr Cardiol 2012;18 [Epub ahead of print].
43. Bucharles S., Barberato S.H., Stinghen A.E., Gruber P., Piekala L., Dambiski A.C., et al. Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism. J Ren Nutr 2012, 22:284-291.
44. Hopkins M.H., Owen J., Ahearn T., Fredirko V., Flanders W.D., Jones D.P., et al. Effects of supplementation vitamin D and calcium on biomarkers on inflammation in colorectal adenoma patients: a randomized, controlled clinical trial. Cancer Prev Res 2011, 4:1645-1654.
45. Oxholm A., Oxholm P., Staberg B., Bendtzen K. Expression of interleukin-6-like molecules and tumor necrosis factor after topical treatment of psoriasis with a new vitamin D analogue (MC 903). Acta Derm Venereol 1989, 69:85-90.
46. Abu-Mouch S., Fireman Z., Jarchovsky J., Zeina A.R., Assy N. Vitamin D supplementation improves sustained virological response in chronic hepatitis C (genotype I)-naïve patients. World J Gastroenterol 2011, 17:5184-5190.
47. Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology 2012, 51S:v38-v47.